Literature DB >> 12670127

Interactions between the cytochrome P450 system and the second-generation antipsychotics.

Trevor I Prior1, Glen B Baker.   

Abstract

Awareness of the metabolism of second-generation antipsychotics by the cytochrome P450 (CYP) system can inform the clinician about how to avoid and manage drug-drug interactions involving these enzymes. Clozapine is metabolized primarily by CYP1A2, with additional contributions by CYP2C19, CYP2D6 and CYP3A4. Risperidone is metabolized primarily by CYP2D6 and to a lesser extent by CYP3A4. Olanzapine is metabolized primarily by CYP1A2 and to a lesser extent by CYP2D6. Quetiapine and ziprasidone are metabolized by CYP3A4. At the usual clinical doses, these drugs appear not to significantly affect the metabolism of other medications. There is, however, a lack of in vivo metabolic data, especially for the 3 newest second-generation antipsychotics: olanzapine, quetiapine and ziprasidone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12670127      PMCID: PMC161731     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  113 in total

1.  Absence of interaction between erythromycin and a single dose of clozapine.

Authors:  S Hägg; O Spigset; T Mjörndal; K Granberg; G Persbo-Lundqvist; R Dahlqvist
Journal:  Eur J Clin Pharmacol       Date:  1999-05       Impact factor: 2.953

2.  Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men.

Authors:  W L Macias; R F Bergstrom; B J Cerimele; K Kassahun; D E Tatum; J T Callaghan
Journal:  Pharmacotherapy       Date:  1998 Nov-Dec       Impact factor: 4.705

3.  Pharmacokinetic interaction of clozapine and rifampicin in a forensic patient with an atypical mycobacterial infection.

Authors:  A A Joos; U G Frank; W P Kaschka
Journal:  J Clin Psychopharmacol       Date:  1998-02       Impact factor: 3.153

4.  An introduction to enantiomers in psychopharmacology.

Authors:  Brian E. Leonard
Journal:  Hum Psychopharmacol       Date:  2001-12       Impact factor: 1.672

5.  Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.

Authors:  C Prakash; A Kamel; D Cui; R D Whalen; J J Miceli; D Tweedie
Journal:  Br J Clin Pharmacol       Date:  2000       Impact factor: 4.335

Review 6.  Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation.

Authors:  E L LeCluyse
Journal:  Eur J Pharm Sci       Date:  2001-07       Impact factor: 4.384

7.  Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.

Authors:  U Jeppesen; L F Gram; K Vistisen; S Loft; H E Poulsen; K Brøsen
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

8.  Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication.

Authors:  O V Olesen; K Linnet
Journal:  Ther Drug Monit       Date:  1999-02       Impact factor: 3.681

9.  Coadministration of clozapine and fluvoxamine in psychotic patients--clinical experience.

Authors:  C H Lammers; M Deuschle; H Weigmann; S Härtter; C Hiemke; C Heese; I Heuser
Journal:  Pharmacopsychiatry       Date:  1999-03       Impact factor: 5.788

10.  Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine.

Authors:  B J Ring; J Catlow; T J Lindsay; T Gillespie; L K Roskos; B J Cerimele; S P Swanson; M A Hamman; S A Wrighton
Journal:  J Pharmacol Exp Ther       Date:  1996-02       Impact factor: 4.030

View more
  35 in total

1.  Toxic clozapine serum levels during acute urinary tract infection: a case report.

Authors:  Julia Jecel; Tanja M Michel; Lise Gutknecht; Daniela Schmidt; Bruno Pfuhlmann; Burkhard E Jabs
Journal:  Eur J Clin Pharmacol       Date:  2005-01-19       Impact factor: 2.953

2.  Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.

Authors:  Jun-Sheng Wang; Hao-Jie Zhu; John S Markowitz; Jennifer L Donovan; C Lindsay DeVane
Journal:  Psychopharmacology (Berl)       Date:  2006-06-30       Impact factor: 4.530

Review 3.  [Differences between men and women in side effects of second-generation antipsychotics].

Authors:  W Aichhorn; A B Whitworth; E M Weiss; H Hinterhuber; J Marksteiner
Journal:  Nervenarzt       Date:  2007-01       Impact factor: 1.214

Review 4.  Clinically significant drug interactions with atypical antipsychotics.

Authors:  William Klugh Kennedy; Michael W Jann; Eric C Kutscher
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

Review 5.  Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?

Authors:  Wolfgang Aichhorn; Alexandra B Whitworth; Elisabeth M Weiss; Josef Marksteiner
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 6.  Coprescription of tamoxifen and medications that inhibit CYP2D6.

Authors:  Kostandinos Sideras; James N Ingle; Matthew M Ames; Charles L Loprinzi; David P Mrazek; John L Black; Richard M Weinshilboum; John R Hawse; Thomas C Spelsberg; Matthew P Goetz
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

7.  Pharmacotherapy for smoking cessation in schizophrenia: a systematic review.

Authors:  Karolina Kozak; Tony P George
Journal:  Expert Opin Pharmacother       Date:  2020-02-03       Impact factor: 3.889

8.  The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications.

Authors:  Jan van der Weide; John W J Hinrichs
Journal:  Clin Biochem Rev       Date:  2006-02

9.  Evaluation of potential pharmacokinetic drug-drug interaction between armodafinil and risperidone in healthy adults.

Authors:  Mona Darwish; Mary Bond; Ronghua Yang; Edward T Hellriegel; Philmore Robertson
Journal:  Clin Drug Investig       Date:  2015-11       Impact factor: 2.859

Review 10.  Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions.

Authors:  Mahmoud Slim; Inmaculada Medina-Caliz; Andres Gonzalez-Jimenez; M Rosario Cabello; Fermin Mayoral-Cleries; M Isabel Lucena; Raul J Andrade
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.